

AFGHANISTAN COVAX TA PLAN				Milestones				Budget for 2020		TOTAL
Country	Programmatic Area	Activity	Partner	January 2021	March 2021	June 2021	November 2021	Expected Duration of Activity	Expected Outcome	
Afghanistan	Planning & Coordination	National coordinator for introduction of COVID-19 vaccine sitting at MoPH	UNICEF	Reports of COVID-19 related activities coordinated among partners through existing coordination platforms/mechanisms	Reports of COVID-19 related activities coordinated among partners through existing coordination platforms/mechanisms	Reports of COVID-19 related activities coordinated among partners through existing coordination platforms/mechanisms	Reports of COVID-19 related activities coordinated among partners through existing coordination platforms/mechanisms	more than 3 months	Coverage of COVID-19 vaccine for the target population groups	\$613,274.76
Afghanistan	Planning & Coordination	National planning consultant for introduction of COVID-19 vaccine sitting at MoPH	UNICEF	Plan for all six sub-committees are available	Plan for all six sub-committees are available	Plan for all six sub-committees are available	Plan for all six sub-committees are available	more than 3 months	Coverage of COVID-19 vaccine for the target population groups	
Afghanistan	Planning & Coordination	Regional Coordinators sitting at the regional DoPH departments and responsible for coordination of COVID-19 vaccine introduction in each region	UNICEF	Action plan for 34 provinces	Action plan for 34 provinces	Action plan for 34 provinces	Action plan for 34 provinces	more than 3 months	Coverage of COVID-19 vaccine for the target population groups	
Afghanistan	Demand Generation & Communication	National Communication officer sitting at MoPH and coordinating demand generation related activities for COVID-19 vaccine introduction for the country	UNICEF	Demand generation action plan for COVID-19 vaccine introduction available	# of IEC materials and media spots developed and ready for use	# of IEC materials distributed and media spots broadcasted	# of IEC materials distributed and media spots broadcasted	more than 3 months	Coverage of COVID-19 vaccine for the target population groups	One staff for 12 months
Afghanistan	Monitoring & Evaluation	Field monitoring for quality assurance of all COVID-19 related interventions across the country by MoPH, UNICEF and field extension	UNICEF	# of field monitoring trip conducted and findings shared through formal reports and action taken	# of field monitoring trip conducted and findings shared through formal reports and action taken	# of field monitoring trip conducted and findings shared through formal reports and action taken	# of field monitoring trip conducted and findings shared through formal reports and action taken	more than 3 months	Coverage of COVID-19 vaccine for the target population groups	Cost of travel, transportation, monitoring management
Afghanistan	Demand Generation & Communication	Designing, developing and finalization of IEC materials (posters, leaflets, stickers, standees, brochures) launching events, mobile ring back tune, media spots and formative small scale study	UNICEF	IEC materials and media spots developed and ready for use	IEC materials and media spots developed and ready for use	IEC materials and media spots developed and ready for use	IEC materials and media spots developed and ready for use	more than 3 months	# of population received COVID-19 key messages	Cost of designing, developing and distributing IEC materials and media management
Afghanistan	Planning & Coordination	A.3 Establish or engage existing NTWG subcommittees, if required, to cover the following workstreams: 1) service delivery 2) vaccine, cold chain & logistics, 3) demand generation & communication 4) prioritization, targeting and COVID-19 surveillance, 5) Monitoring and Evaluation: determination and proof of eligibility, proof of vaccination, monitoring of coverage among at-risk groups, and monitoring of vaccine impact 6) Safety, including injury prevention and AEFI detection and response, established or if pre-existing, engaged	WHO	NTWG subcommittees for the following workstreams: 1) service delivery 2) vaccine, cold chain & logistics, 3) demand generation & communication 4) prioritization, targeting and COVID-19 surveillance, 5) Monitoring and Evaluation: determination and proof of eligibility, proof of vaccination, monitoring of coverage among at-risk groups, and monitoring of vaccine impact 6) Safety, including injury prevention and AEFI detection and response, established or if pre-existing, engaged	Established NTWG subcommittees for the following workstreams: 1) service delivery 2) vaccine, cold chain & logistics, 3) demand generation & communication 4) prioritization, targeting and COVID-19 surveillance, 5) Monitoring and Evaluation: determination and proof of eligibility, proof of vaccination, monitoring of coverage among at-risk groups, and monitoring of vaccine impact 6) Safety, including injury prevention and AEFI detection and response, established or if pre-existing, engaged	NTWG subcommittees for the following workstreams: 1) service delivery 2) vaccine, cold chain & logistics, 3) demand generation & communication 4) prioritization, targeting and COVID-19 surveillance, 5) Monitoring and Evaluation: determination and proof of eligibility, proof of vaccination, monitoring of coverage among at-risk groups, and monitoring of vaccine impact 6) Safety, including injury prevention and AEFI detection and response, established or if pre-existing, engaged	NTWG subcommittees for the following workstreams: 1) service delivery 2) vaccine, cold chain & logistics, 3) demand generation & communication 4) prioritization, targeting and COVID-19 surveillance, 5) Monitoring and Evaluation: determination and proof of eligibility, proof of vaccination, monitoring of coverage among at-risk groups, and monitoring of vaccine impact 6) Safety, including injury prevention and AEFI detection and response, established or if pre-existing, engaged	0.1 month	Planning	Field visits for readiness assessment and mapping of health facilities for vaccine deployment (travel costs) and development and submission of NDVP
Afghanistan	Planning & Coordination	A.5 Inform regulatory & disseminate global and regional guidance (i.e. SACD) with NITAGs & RITAGs and support NITAG working groups on COVID-19 vaccines	WHO	Global and regional guidance disseminated to NITAGs & RITAGs and NITAG working groups on COVID-19 vaccines	Global and regional guidance disseminated to NITAGs & RITAGs and NITAG working groups on COVID-19 vaccines	Global and regional guidance disseminated to NITAGs & RITAGs and NITAG working groups on COVID-19 vaccines	Global and regional guidance disseminated to NITAGs & RITAGs and NITAG working groups on COVID-19 vaccines	more than 3 months	Timely dissemination of guidelines to NITAG members	Printing cost
Afghanistan	Safety Surveillance	I.6 Establish a coordination mechanism between relevant stakeholders (NRA, EPI, MAM, MoH, WHO and others) for exchange of COVID-19 Vaccine safety information	WHO	AEFI committee to review COVID-19 Vaccine safety data (e.g. causality assessment of serious AEFI, clusters of AEFI, emerging safety concerns etc.) is trained	Guidelines, documented procedures and tools for planning and conducting vaccine pharmacovigilance activities (i.e. AEFI reporting, investigation, causality assessment, risk communication and response) are made available	Competent and trained staff to perform vigilance activities	Active surveillance of specific COVID-19 vaccine intended adverse events is planned for	more than 3 months	Vaccine safety monitoring, management of adverse events, following immunization and injection safety	The estimated cost include developing of guideline, tools, printing and training of 24 trainers, 10 supervisors, 80 national and provincial pharmacovigilance staff on Covid 19 vaccine AEFI and active surveillance field visits (transport cost)
Afghanistan	Regulatory Aspects	C.1 Confirm to WHO the existence of any expedited regulatory pathway for approval of COVID-19 vaccines (i.e. emergency use authorization, exceptional approval/waiver mechanism based on reliance/recognition, abbreviated procedure, fast track, etc.)	WHO	Expedited regulatory pathway for approval of COVID-19 vaccines (i.e. emergency use authorization, exceptional approval/waiver mechanism based on reliance/recognition, abbreviated procedure, fast track, etc.) identified and confirmed.	Review of summary protocols is completed, and a system of waiving local lot release testing based on the review is established	Expedited import approval/waiver from appropriate authorities identified and confirmed with WHO.	Expedited import approval/waiver from appropriate authorities identified and confirmed with WHO.	more than 3 months	Identify pathways for emergency regulatory approval based on proper regulatory decision-making in a time-efficient manner	Meetings and communication with relevant departments and Ministries
Afghanistan	Training & Supervision	F.2 Adapt and translate training materials developed by WHO and develop additional training materials as outlined in the training plan	WHO	Training materials developed by WHO adapted and translated, as well as additional training materials developed as required.	Trainings conducted as per the training plan.	Trainings conducted as per the training plan.	Trainings conducted as per the training plan.	0.1 month	Plan to adequately address the human resource	The estimated cost include training materials, tools, printing, and conducting National TOT for 24 master trainers, regional TOT for 170 provincial staff (REMT, REMT, EPI supervisors and Data officers, provincial cascade training for 890 health workers.
Afghanistan	Service Delivery	E.2 Identify potential COVID-19 vaccine delivery strategies leveraging both existing vaccination platforms and non-vaccination delivery approaches to best reach identified target groups	WHO	Potential COVID-19 vaccine delivery strategy identified to best reach target groups.	Plans for safeguarding the security of staff (e.g. during an emergency or major campaign) as well as security at the central and/or regional storage facilities and for transit of products developed.	Potential COVID-19 vaccine delivery strategy identified to best reach target groups.	Potential COVID-19 vaccine delivery strategy identified to best reach target groups.	more than 3 months	Availability of potential vaccine delivery strategies vaccine based on expected vaccine schedule and recommendations for administration & procedure for infection prevention	Guideline for personnel protective measures during Covid 19 vaccine deployment and orientation of 86 staff
Afghanistan	Monitoring & Evaluation	G.3 Produce and distribute monitoring tools to eligible vaccination providers, develop, test and roll-out any changes to electronic systems, provide training for use of these tools and processes to traditional and new providers	WHO	Necessary monitoring tools developed or existing tools (vaccination card/certificate - facility-based nominal registers and/or tally sheets, vaccination reports (paper and/or electronic) adapted and analytical tools to monitor progress and coverage among different at-risk categories developed.	Existing surveillance and monitoring framework with a set of recommended indicators (coverage, acceptability, disease surveillance etc.) for COVID-19 vaccine developed or adapted.	Existing surveillance and monitoring framework with a set of recommended indicators (coverage, acceptability, disease surveillance etc.) for COVID-19 vaccine developed or adapted.	Existing surveillance and monitoring framework with a set of recommended indicators (coverage, acceptability, disease surveillance etc.) for COVID-19 vaccine developed or adapted.	1-2 months	Identification of data needs and strengthen information systems to monitor progress with Covid 19 vaccination & definition of indicators to monitor progress and adapt current COVID-19 disease surveillance to meet vaccination surveillance objectives.	Design a system to record, report, analyse and use vaccination data & Develop a database and a COVID-19 vaccination dashboard
Afghanistan	Monitoring & Evaluation	G.2 Develop or adapt necessary monitoring tools or adapt existing tools, vaccination card/certificate - facility-based nominal registers and/or tally sheets, vaccination reports (paper and/or electronic) adapted and analytical tools to monitor progress and coverage among different at-risk categories	WHO	Necessary monitoring tools developed or existing tools (vaccination card/certificate - facility-based nominal registers and/or tally sheets, vaccination reports (paper and/or electronic) adapted and analytical tools to monitor progress and coverage among different at-risk categories developed.	Existing surveillance and monitoring framework with a set of recommended indicators (coverage, acceptability, disease surveillance etc.) for COVID-19 vaccine developed or adapted.	Existing surveillance and monitoring framework with a set of recommended indicators (coverage, acceptability, disease surveillance etc.) for COVID-19 vaccine developed or adapted.	Existing surveillance and monitoring framework with a set of recommended indicators (coverage, acceptability, disease surveillance etc.) for COVID-19 vaccine developed or adapted.	more than 3 months	National, regional, provincial and district and HF level monitoring and supervision	
Afghanistan	Monitoring & Evaluation	G.1 Develop or adapt existing surveillance and monitoring framework with a set of recommended indicators (coverage, acceptability, disease surveillance etc.) for COVID-19 vaccine. Determine whether registration and reporting will be individual or aggregate, and to what extent existing tools and systems can be re-used	WHO	Necessary monitoring tools developed or existing tools (vaccination card/certificate - facility-based nominal registers and/or tally sheets, vaccination reports (paper and/or electronic) adapted and analytical tools to monitor progress and coverage among different at-risk categories developed.	Existing surveillance and monitoring framework with a set of recommended indicators (coverage, acceptability, disease surveillance etc.) for COVID-19 vaccine developed or adapted.	Existing surveillance and monitoring framework with a set of recommended indicators (coverage, acceptability, disease surveillance etc.) for COVID-19 vaccine developed or adapted.	Existing surveillance and monitoring framework with a set of recommended indicators (coverage, acceptability, disease surveillance etc.) for COVID-19 vaccine developed or adapted.	more than 3 months	Post introduction Evaluation (PIE) is to adapt tools to a P1E What is this	

